These three dividends look cheap, yet compelling right now.
News & Analysis: Momenta Pharmaceuticals
These three incredible stocks have multibagger potential if you hold them for decades.
The Fed spoiled the party for the stock market.
A healthcare titan is acquiring the biotech in a $6.5 billion deal.
The company is paying a big premium to expand its autoimmune disease treatment footprint.
No news is apparently bad news.
MNTA earnings call for the period ending June 30, 2020.
Positive phase 2 clinical trial data puts the biotech's lead drug candidate on a good path forward.
Here’s why this drugmaker targeting autoimmune conditions and rare diseases is a solid buy.
MNTA earnings call for the period ending March 31, 2020.